Dimerix CEO Details $1.9 Billion Kidney Pipeline and New Phase 2 Asset

Dimerix Highlights $1.9 Billion Licensing Milestone Potential

At the 20th Bioshares Biotech Summit in Queenstown, Dimerix Limited (ASX:DXB) CEO Dr Nina Webster outlined a robust diversification strategy underpinning the company’s kidney disease pipeline. Central to this is the commercialisation of DMX-200, a Phase 3 candidate for focal segmental glomerulosclerosis (FSGS), which boasts five licensing deals across key global markets valued collectively at up to A$1.9 billion in upfront, milestone payments, and royalties.

The licensing footprint spans the United States, Europe, Canada, Australia, New Zealand, Japan, China, South Korea, Southeast Asia, and the Gulf Cooperation Council, providing Dimerix with diversified revenue streams and reduced dependence on any single regulatory or reimbursement environment. This multi-region approach not only broadens patient access but also enhances resilience against economic and policy fluctuations.

DMX-200 Advances with Full Adult Recruitment and Strong Trial Metrics

The ACTION3 Phase 3 trial for DMX-200 in FSGS has completed adult patient recruitment with 333 participants randomized and dosed, surpassing the target of 286. A blinded interim assessment confirmed the trial remains statistically powered (>90%) to meet its primary proteinuria endpoint, a key marker of kidney function. This progress supports the potential for regulatory submissions and commercial launches across licensed territories in the coming years.

FSGS remains a serious, rare kidney disorder with limited treatment options and high unmet need. DMX-200’s mechanism as a CCR2 antagonist targets inflammatory pathways implicated in disease progression, distinguishing it from existing non-specific immunosuppressive therapies. The drug carries orphan designations in the US, Europe, UK, and Japan, offering regulatory and market exclusivity benefits.

DMX-652 Acquisition Adds Phase 2-Ready Asset Targeting Acute Kidney Injury

Dimerix’s pipeline expansion continued with the acquisition of DMX-652, a first-in-class, oral USP30 inhibitor designed to prevent acute kidney injury (AKI) in high-risk patients undergoing cardiac surgery. AKI is a rapid-onset condition with no approved therapies, affecting an estimated 260,000 patients annually across major markets including the US, Europe, and Australia.

DMX-652 has cleared a US FDA open Investigational New Drug (IND) status with an approved Phase 2 clinical trial protocol. The trial, expected to commence patient dosing in H1 2027, will evaluate safety and efficacy in a double-blind, placebo-controlled design involving approximately 160 patients across ~25 sites. The asset’s acquisition includes granted patents extending to 2042, GMP-grade drug supply, and manufacturing methodologies, mitigating early development risks.

This complementary asset leverages Dimerix’s existing renal disease expertise and infrastructure, offering a new growth engine alongside DMX-200. The company emphasised the strategic fit between the two assets, with shared clinical, regulatory, and commercial capabilities enhancing operational efficiency.

Corporate Financials and Strategic Outlook

As of June 2026, Dimerix holds $16.2 million in cash, excluding approximately $24 million in upcoming payments from Everest Medicines’ upfront licensing fee and a $10 million loan facility. The company’s market capitalisation stands at $174 million, with a share price of $0.29 and daily liquidity averaging $0.85 million over the past 90 trading days.

Dr Webster’s presentation underscored a disciplined, stage-gated capital deployment strategy focused on clinical value inflection points, including pediatric recruitment completion, Phase 3 readouts for DMX-200, and Phase 2 milestones for DMX-652. These upcoming catalysts are expected to shape investor sentiment and market positioning over the next two years.